Oak Hill Bio: A Message to the Angelman Syndrome Community
Following the recent announcement on the outcome of the phase 3 Aspire trial of GTX-102, Oak Hill Bio has shared a message about their commitment to evaluate rugonersen in their ongoing Phase 3 BEACON trial. Read the letter here
Rugonersen Development Update: First Participant Dosed in the Phase 3 BEACON Trial
Oak Hill Bio shares a community letter marking the first participant dosed in its BEACON study, thanking families and investigators for making this milestone possible.
Update on Rugonersen Development and Planned Phase 3 Study (BEACON)
Oak Hill Bio shared an update on rugonersen’s development, preparing to launch its Phase 3 study in mid-2026. Eligibility details are now available on clinicaltrials.gov.
Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine
Oak Hill Bio’s Phase 1 TANGELO study results, published in Nature Medicine, show improvements in brain activity and development for children with Angelman syndrome on rugonersen.
Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roche.
Oak Hill Bio has entered into an exclusive global licensing agreement with Roche to acquire and advance rugonersen, a Phase 3-ready investigational ASO treatment for Angelman syndrome.
An update on Roche’s trials of rugonersen (RO7248824) in Angelman syndrome
We are sad to report that Roche has decided they will not initiate any new trials of rugonersen (RO7248824) in Angelman syndrome. If you are currently participating in the study, you should be hearing from the Investigator or their team at the site where your child is enrolled regarding important information about next steps for your […]